StreetInsider.com News Articles

Form 6-K Evaxion A/S For: Jul 17

Fri, 17 Jul 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260717/26781926.html

Form 6-K Evaxion A/S For: Jul 17

Fri, 17 Jul 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260717/26781926.html

Evaxion to present 3-year cancer vaccine data at ESMO 2026

Fri, 17 Jul 2026 07:15:45 -0400

Evaxion A/S (NASDAQ: EVAX) said it will present three-year clinical efficacy data from its phase 2 trial of personalized cancer vaccine candidate EVX-01 at the European Society for Medical Oncology (ESMO) Congress 2026, scheduled for October 23-27 in Madrid, Spain.

The data comes from a one-year extension of the phase 2 trial evaluating EVX-01 in patients with advanced melanoma. During the third year of the trial, a subset of patients received EVX-01 as a stand-alone therapy, without combination with anti-PD-1 treatment.

Previously reported two-year data from the trial showed an Objective Response Rate of 75%, with 12 out of 16 patients achieving

Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026

Fri, 17 Jul 2026 07:15:00 -0400

Three-year data from phase 2 trial will provide additional insights into potentially enhanced treatment effects and durability of the EVX-01-induced immune response
Data will also offer insight into the vaccine’s effect also as stand-alone treatment of patients with advanced melanoma
Unprecedented two-year data from the trial presented last year showed high response rates and an impressive durability of responses

COPENHAGEN, Denmark, July 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will present three-year clinical efficacy data from its phase 2 trial with

Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026

Fri, 17 Jul 2026 07:15:00 -0400

Three-year data from phase 2 trial will provide additional insights into potentially enhanced treatment effects and durability of the EVX-01-induced immune response
Data will also offer insight into the vaccine’s effect also as stand-alone treatment of patients with advanced melanoma
Unprecedented two-year data from the trial presented last year showed high response rates and an impressive durability of responses

Form 6-K Evaxion A/S For: Jul 12

Mon, 13 Jul 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260713/26759169.html

Form 6-K Evaxion A/S For: Jul 12

Mon, 13 Jul 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260713/26759169.html

Evaxion shares preclinical data for CMV vaccine program EVX-V1

Sun, 12 Jul 2026 09:30:15 -0400

Evaxion A/S (NASDAQ: EVAX) presented new preclinical data for its cytomegalovirus (CMV) vaccine program, EVX-V1, at the International Herpesvirus Workshop in Montreal, Canada, on July 12, 2026.

The data show that AI-discovered T-cell epitopes used in the program have the potential to improve control of acute infection, latency, and viral reactivation in CMV-infected mice. This adds to earlier findings in which novel B-cell antigens reduced viral infection in preclinical models, and AI-optimized structural B-cell antigens demonstrated enhanced viral neutralization.

EVX-V1 is a multi-component vaccine candidate that combines novel antigens identified through Evaxion's AI-Immunology platform with AI-optimized versions of established CMV vaccine antigens.

Evaxion shares preclinical data for CMV vaccine program EVX-V1

Sun, 12 Jul 2026 09:30:15 -0400

Evaxion A/S (NASDAQ: EVAX) presented new preclinical data for its cytomegalovirus (CMV) vaccine program, EVX-V1, at the International Herpesvirus Workshop in Montreal, Canada, on July 12, 2026.

The data show that AI-discovered T-cell epitopes have the potential to improve control of acute infection, latency, and viral reactivation in CMV-infected mice. This adds to earlier findings in which novel B-cell antigens reduced viral infection in preclinical models and AI-optimized structural B-cell antigens demonstrated viral neutralization.

EVX-V1 is described by the company as a multi-component vaccine program that combines novel AI-discovered antigens with AI-optimized versions of established CMV vaccine antigens. No CMV vaccine has

Evaxion shares preclinical data for CMV vaccine program EVX-V1

Sun, 12 Jul 2026 09:30:15 -0400

Evaxion A/S (NASDAQ: EVAX) presented new preclinical data for its cytomegalovirus (CMV) vaccine program, EVX-V1, at the International Herpesvirus Workshop in Montreal, Canada, on July 12, 2026.

EVX-V1 is described by the company as a multi-component vaccine program that combines novel AI-discovered antigens with AI-optimized versions of established CMV vaccine antigens. No CMV vaccine has

Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1